EcoDrugPlus

Protein Phosphatase 3, Catalytic Subunit, Alpha Isoform

Ensembl ID : ENSMSIG00000025033
Gene Symbol: PPP3CA
1 Cross references
245 Possible Orthologues:

Protein Tyrosine Phosphatase, Non-Receptor Type 11

Ensembl ID : ENSMSIG00000010427
Gene Symbol: PTPN11
1 Cross references
266 Possible Orthologues:

Protein Tyrosine Phosphatase, Receptor Type, B

Ensembl ID : ENSMSIG00000008638
Gene Symbol: PTPRB
1 Cross references
279 Possible Orthologues:

Proviral Integration Site 1

Ensembl ID : ENSMSIG00000010559
Gene Symbol: PIM1
1 Cross references
259 Possible Orthologues:

Proviral Integration Site 3

Ensembl ID : ENSMSIG00000021238
Gene Symbol: PIM3
1 Cross references
232 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3

Ensembl ID : ENSMSIG00000001910
Gene Symbol: P2RX3
1 Cross references
285 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSMSIG00000013522
Gene Symbol: P2RX7
1 Cross references
202 Possible Orthologues:

Purinergic Receptor P2y, G-Protein Coupled 1

Ensembl ID : ENSMSIG00000019249
Gene Symbol: P2RY1
1 Cross references
205 Possible Orthologues:

Purinergic Receptor P2y, G-Protein Coupled 12

Ensembl ID : ENSMSIG00000026846
Gene Symbol: P2RY12
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y, G-Protein Coupled 2

Ensembl ID : ENSMSIG00000028156
Gene Symbol: P2RY2
1 Cross references
212 Possible Orthologues:

Pyrimidinergic Receptor P2y, G-Protein Coupled, 4

Ensembl ID : ENSMSIG00000003970
Gene Symbol: P2RY4
1 Cross references
180 Possible Orthologues:

Pyrimidinergic Receptor P2y, G-Protein Coupled, 6

Ensembl ID : ENSMSIG00000028155
Gene Symbol: P2RY6
1 Cross references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).